Today's Daily Dose brings you news about disappointing trial results of Aevi Genomic; progress in Allena's phase III program of Reloxaliase; FDA approval of Bristol-Myers' blockbuster Sprycel for another indication; and update on Flexion's phase III trial of ZILRETTA in patients with hip osteoarthritis.
from RTT - Biotech http://bit.ly/2C1xXZY
via IFTTT
No comments:
Post a Comment